Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. The third stock on our list is BridgeBio Pharma, Inc.

TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating. The firm updated its model but noted in a research note that its fundamental views remain unchanged from 2025.

Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results

In keeping with this positive view, on January 12, BridgeBio Pharma, Inc. (NASDAQ:BBIO) gave a significant operational update at the 44th Annual J.P. Morgan Healthcare Conference. For Attruby, the firm announced preliminary unaudited revenues of $146.0 million for the fourth quarter of 2025, totaling $362.4 million in product revenue for the full year of 2025. This accomplishment amply illustrates the rapid market adoption of Attruby as a first-choice treatment for newly diagnosed ATTR-CM patients, with over 6,000 unique prescriptions written by the end of 2025.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) develops therapies for genetic diseases and cancers, supporting its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT), which advances precision cancer treatments targeting key oncogenes like RAS and PI3K into clinical trials.

While we acknowledge the risk and potential of BBIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BBIO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.